279 related articles for article (PubMed ID: 26804670)
21. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.
Kaapu KJ; Murtola TJ; Määttänen L; Talala K; Taari K; Tammela TL; Auvinen A
Cancer Causes Control; 2016 Feb; 27(2):157-64. PubMed ID: 26573846
[TBL] [Abstract][Full Text] [Related]
23. Association of 5α-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy.
Hong SK; Oh JJ; Lee S; Lee HM; Byun SS; Choe G; Lee SE
Prostate; 2012 Aug; 72(11):1187-92. PubMed ID: 22161951
[TBL] [Abstract][Full Text] [Related]
24. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial.
Murtola TJ; Tammela TL; Määttänen L; Huhtala H; Platz EA; Ala-Opas M; Stenman UH; Auvinen A
Int J Cancer; 2010 Oct; 127(7):1650-9. PubMed ID: 20073066
[TBL] [Abstract][Full Text] [Related]
26. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors.
Mäkelä VJ; Kotsar A; Tammela TLJ; Murtola TJ
J Urol; 2018 Oct; 200(4):743-748. PubMed ID: 29730200
[TBL] [Abstract][Full Text] [Related]
27. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.
Murtola TJ; Kasurinen TVJ; Talala K; Taari K; Tammela TLJ; Auvinen A
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):66-76. PubMed ID: 30214034
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer mortality in the Finnish randomized screening trial.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.
Murtola TJ; Vettenranta AM; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
Eur Urol Focus; 2018 Dec; 4(6):851-857. PubMed ID: 28753870
[TBL] [Abstract][Full Text] [Related]
30. Association of 5α-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea.
An MH; Kim MS; Kim C; Noh TI; Joo KJ; Lee DH; Yi KH; Kwak JW; Hwang TH; Park RW; Kang SH
JAMA Netw Open; 2023 May; 6(5):e2313667. PubMed ID: 37191958
[TBL] [Abstract][Full Text] [Related]
31. Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study.
Wallerstedt A; Strom P; Gronberg H; Nordstrom T; Eklund M
J Natl Cancer Inst; 2018 Nov; 110(11):1216-1221. PubMed ID: 29548030
[TBL] [Abstract][Full Text] [Related]
32. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
33. Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Kinnunen PT; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2016 Dec; 50(6):413-419. PubMed ID: 27628763
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.
Murtola TJ; Tammela TL; Määttänen L; Ala-Opas M; Stenman UH; Auvinen A
Br J Cancer; 2009 Sep; 101(5):843-8. PubMed ID: 19654575
[TBL] [Abstract][Full Text] [Related]
35. 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Richert-Boe K; Horwitz RI; Jacobsen SJ
Mayo Clin Proc; 2016 Dec; 91(12):1717-1726. PubMed ID: 28126151
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means.
Sakai N; Taguri M; Kobayashi K; Noguchi S; Ikeda S; Koh H; Satomi Y; Furuhata A
Int J Urol; 2015 Aug; 22(8):747-52. PubMed ID: 26011393
[TBL] [Abstract][Full Text] [Related]
37. Improved multiparametric MRI discrimination between low-risk prostate cancer and benign tissues in a small cohort of 5α-reductase inhibitor treated individuals as compared with an untreated cohort.
Starobinets O; Kurhanewicz J; Noworolski SM
NMR Biomed; 2017 May; 30(5):. PubMed ID: 28164396
[TBL] [Abstract][Full Text] [Related]
38. [Opportunities and risks of 5α reductase inhibitors in the medical management of Active surveillance for localized prostate cancer].
Linares Espinos E; Carballido Rodriguez J
Arch Esp Urol; 2014 Jun; 67(5):457-61. PubMed ID: 24914845
[TBL] [Abstract][Full Text] [Related]
39. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
40. Use of 5α-reductase inhibitors for benign prostate hypertrophy and risk of high grade prostate cancer: a French population-based study.
Scailteux LM; Rioux-Leclercq N; Vincendeau S; Balusson F; Nowak E; Oger E;
BJU Int; 2019 Feb; 123(2):293-299. PubMed ID: 30025199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
